ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 247 filers reported holding ACCELERON PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $960,000 | +29.7% | 5,576 | -5.5% | 0.01% | +27.3% |
| Q2 2021 | $740,000 | -10.4% | 5,900 | -3.1% | 0.01% | -15.4% |
| Q1 2021 | $826,000 | +3.5% | 6,088 | -2.4% | 0.01% | 0.0% |
| Q4 2020 | $798,000 | +5.8% | 6,237 | -7.0% | 0.01% | -13.3% |
| Q3 2020 | $754,000 | +471.2% | 6,703 | +356.6% | 0.02% | +400.0% |
| Q1 2020 | $132,000 | +63.0% | 1,468 | -4.2% | 0.00% | +50.0% |
| Q4 2019 | $81,000 | +32.8% | 1,532 | -0.2% | 0.00% | +100.0% |
| Q3 2019 | $61,000 | -9.0% | 1,535 | -5.8% | 0.00% | 0.0% |
| Q2 2019 | $67,000 | -23.9% | 1,629 | -14.1% | 0.00% | -50.0% |
| Q1 2019 | $88,000 | -22.1% | 1,896 | -26.9% | 0.00% | -33.3% |
| Q4 2018 | $113,000 | +352.0% | 2,594 | +209.9% | 0.00% | +200.0% |
| Q2 2017 | $25,000 | +13.6% | 837 | -1.4% | 0.00% | 0.0% |
| Q1 2017 | $22,000 | – | 849 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |